Evidence for Permax heart valve injury has increased as a result of new research published in the March 2007 issue of the medical journal Archives of Neurology. This study provides further support for problems related to Permax. Damage to the heart valve was found to increase with long-term use of the drug. The purpose of this study was to compare Permax patients with patients treated with drugs Mirapex and Requip.
Permax (Pedaxlide) has been on the market since 1989. Permax is prescribed for the treatment of Parkinson's disease patients and those suffering from restless leg syndrome. As concerns about side effects due to permanent heart valve damage increased, in 2006 black box warnings were added to the label of this drug.
Recent studies have evaluated whether damages to heart valves of permalinks associated with prolonged use of drugs in the UK and Italy are serious problems. In the UK study, 11,417 people were given permanents. Subjects were 37 times more likely to develop cardiac problems. In Italy 's research 155 people with Parkinson' s disease who was taking Parmex participated. 23.4% of people who ingested drugs in the study reported damage to the heart valve.
In the Mayo Clinic, problems related to permanent heart valve injuries have also been reported. According to Mayo Clinic doctors, three patients who took Parmax for 3 to 7 years suffered severe heart valve injury. Two of the patients had serious cardiac injury requiring valve replacement surgery. Mayo Clinic doctors advised that patients with heart problems should not take medication, given the risk associated with permax.
Symptoms of permanmark heart valve injuries include chest pain, shortness of feet, swelling of the feet and ankles. In some cases, patients with severe heart valve injury may require heart valve replacement, or if left untreated, they may die from suffering heart failure.
Damage to the heart valve prevents opening and closing of the valve. There are two main types of heart valve disease. Stenosis (occlusion) occurs when the opening of the valve narrows and it is difficult to pump blood into the body. Backflow (inadequate) is to prevent the valve from being completely closed and preventing the blood from leaking backward rather than forward.
On 29th March 2007, the FDA announced Permax recall. In light of this recall, the FDA is currently encouraging patients taking this medicine to consider doctors and alternative treatment options and to monitor potential permalink heart valve injury issues.
